Paroxetine

• Major Depressive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Social Anxiety Disorder
• OCD
• PTSD

Paroxetine (brand names Paxil and Paxil CR) is a selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder. It is the most potent serotonin reuptake inhibitor among the SSRIs and the only one with clinically meaningful anticholinergic activity, traits that shape both its clinical niche and its side-effect profile. Paroxetine has been on the market since 1992 and remains a widely prescribed option, although newer SSRIs are often preferred when starting therapy in many patients due to differences in tolerability and discontinuation profile.

Mechanism of Action

Paroxetine binds the serotonin transporter (SERT) on presynaptic neurons, blocking serotonin reuptake from the synaptic cleft and elevating extracellular serotonin concentrations. This acute pharmacologic effect occurs within hours, but clinical benefit emerges over weeks. Sustained signaling is thought to drive downstream neuroplastic changes (BDNF expression, synaptic remodeling, hippocampal neurogenesis, and normalization of HPA axis hyperactivity) that underlie clinical improvement over four to eight weeks. Paroxetine also weakly inhibits norepinephrine reuptake at higher doses and antagonizes muscarinic acetylcholine receptors with affinity that exceeds other SSRIs, which contributes to dry mouth, constipation, urinary retention in susceptible patients, and sedation. It is a potent inhibitor of CYP2D6 (and a substrate as well), creating both autoinhibition of its own metabolism and many drug interactions, particularly with medications that depend on CYP2D6 for activation (codeine, tamoxifen) or clearance (many beta-blockers, antipsychotics, atomoxetine). The National Institute of Mental Health overview provides patient-level context on SSRIs and related agents.

Clinical Use

Paroxetine is effective across the SSRI-responsive disorders, but its profile favors patients in whom mild sedation and anxiolysis are welcome and who are not at high risk for falls, cognitive sensitivity, or anticholinergic burden. It is generally not first choice in older adults, where escitalopram or sertraline are usually preferred for tolerability and cleaner drug interaction profiles. It is contraindicated in pregnancy in most circumstances because of cardiac malformation signals from epidemiologic studies; fluoxetine or sertraline are preferred when an SSRI is needed in pregnancy. Paroxetine is also one of the few medications with a non-hormonal indication for hot flashes (low-dose mesylate formulation, brand name Brisdelle, at 7.5 mg). For comorbid chronic pain, neuropathy, or fibromyalgia, duloxetine or venlafaxine may be more useful given their additional norepinephrine activity. For OCD or PTSD specifically, paroxetine has strong evidence and is a reasonable first-line SSRI choice when the discontinuation issues are acceptable. See our psychiatric care page and our St. Petersburg mental health and anxiety guide for related resources.

How to Take It

Immediate-release paroxetine is taken once daily, usually in the morning to minimize insomnia or in the evening if sedation is a wanted side effect. The controlled-release tablet must be swallowed whole. Food does not significantly alter absorption. Initial doses are typically 10-20 mg with titration over weeks to a target dose; lower starting doses (10 mg or even 5 mg of suspension) are reasonable for anxiety-prone patients to limit early activation. Therapeutic benefit usually begins to emerge in two to four weeks, with full response over six to eight; partial responders at four weeks often improve further with dose optimization. If a dose is missed, take it when remembered unless the next dose is near; do not double up. Paroxetine has the highest incidence of discontinuation syndrome among SSRIs (flu-like symptoms, dizziness, electric-shock sensations called brain zaps, irritability, vivid dreams, gastrointestinal upset), driven by its short half-life of about 21 hours and lack of long-acting metabolites. Any planned stop should be done with a slow taper guided by your physician, often over four to eight weeks or longer; switching to fluoxetine briefly to bridge discontinuation is one strategy when symptoms are severe.

Monitoring and Follow-Up

Follow up at two to four weeks after initiation or dose change to assess tolerability and emerging suicidal ideation, then at six to eight weeks for response, then every three months once stable. There are no required laboratory tests, but a baseline metabolic panel is reasonable to document sodium, since SSRIs can cause hyponatremia (SIADH), particularly in older adults on diuretics; this and other commonly checked values are reviewed in our lab panels overview. Monitor weight, blood pressure, sexual function (which patients often hesitate to bring up unless asked directly), and bleeding history at follow-ups. The PHQ-9 for depression and GAD-7 for anxiety provide structured tracking of response and are especially useful for documenting improvement that patients may underestimate. Bone density may decline modestly with long-term SSRI use, so attention to fracture risk in older adults is reasonable.

Special Populations

In older adults, start at half the usual dose (10 mg IR or 12.5 mg CR) and titrate slowly; the anticholinergic effect can worsen cognition, contribute to constipation, and elevate fall risk through orthostatic hypotension and sedation. Hepatic impairment requires lower starting doses and a maximum of 40 mg IR. Renal impairment with CrCl below 30 mL/min also requires conservative dosing, starting at 10 mg with maximum 40 mg. Paroxetine is generally avoided in pregnancy due to first-trimester cardiac malformation signals (FDA-assigned former Category D); women who become pregnant on the drug should not stop abruptly but should discuss switching with their physician, since the absolute risk increase is small. Excretion into breast milk is low and many infants tolerate maternal use, but monitoring for irritability, poor feeding, or somnolence is appropriate. Pediatric use is not approved for depression because of increased suicidality risk identified in pivotal trials.

CYP2D6 Interactions and Discontinuation Strategy

Paroxetine's potent CYP2D6 inhibition deserves particular attention because of the breadth of medications affected. Tamoxifen depends on CYP2D6 conversion to its active metabolite endoxifen, and concurrent paroxetine has been associated with reduced tamoxifen efficacy in observational studies of breast cancer survivors; this is one of the strongest reasons to avoid paroxetine in this population. Codeine and tramadol require CYP2D6 activation to morphine and O-desmethyltramadol, respectively, and analgesia is reduced when these are coadministered with paroxetine. Atomoxetine, used for ADHD, has dramatically increased exposure with paroxetine and may require dose reduction. Many beta-blockers including metoprolol have markedly elevated levels with paroxetine, occasionally producing bradycardia or hypotension. Several antipsychotics including aripiprazole and risperidone have CYP2D6-dependent metabolism and may need dose adjustment. The combination with tramadol carries dual concerns: reduced analgesia from impaired activation and increased serotonin syndrome risk from the serotonergic activity of tramadol itself. Discontinuation of paroxetine deserves special planning. Because of its short half-life and lack of an active long-acting metabolite (in contrast to fluoxetine, which has a half-life of 4-6 days plus a 7-15 day metabolite), even brief gaps produce withdrawal symptoms in many patients. A common strategy reduces by 25 percent every 2-4 weeks, slowing further at lower doses. The liquid suspension allows fine titration in 1-2 mg decrements at the end of taper. For patients with severe discontinuation symptoms, switching to a single dose of fluoxetine and tapering from there is an effective bridging strategy. Patients should be counseled that discontinuation symptoms are not addiction and do not indicate a need for the medication, but they do reflect a real neurochemical adaptation that requires gradual reversal. Our chronic stress and physical illness article discusses the broader role of stress in mood disorders.

When to Contact Your Doctor

Seek immediate care for new or worsening suicidal thoughts, agitation, or severe restlessness, particularly in patients under 25 in the first weeks of therapy when the boxed warning applies. Symptoms of serotonin syndrome (high fever, rigidity, tremor, agitation, autonomic instability with sweating and tachycardia, hyperreflexia) constitute an emergency, especially if combined with triptans, tramadol, MAOIs, linezolid, or methylene blue. Unusual bleeding or bruising (paroxetine inhibits platelet serotonin uptake), signs of hyponatremia (confusion, headache, weakness, seizures, especially in older adults), or manic symptoms (decreased need for sleep, racing thoughts, impulsive behavior, irritability or grandiosity) warrant prompt evaluation. Never stop paroxetine abruptly without guidance because of severe discontinuation symptoms.

If you are considering an SSRI, struggling with mood or anxiety symptoms, or want to discuss whether paroxetine is the right fit, contact us or schedule a visit.